Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Leveraging computerized maintenance management systems software can enhance efficiency, improve quality control, ensure ...

Choosing dividend stocks is not only about looking at the yield but also ensuring that the company pays regular dividends, ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Trump HHS ends nearly $1 billion in funding to Moderna for mRNA bird flu vaccines, citing safety concerns and lack of ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Real-estate company Metro Loft Developers and David Werner Real Estate Investments, a commercial real-estate investment ...

The drug remained on the Japanese market and had been available to individual patients through Pfizer’s compassionate use schemes. Due to the unmet need for treatments for AML, doctors ...